[go: up one dir, main page]

HUE054204T2 - Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez - Google Patents

Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez

Info

Publication number
HUE054204T2
HUE054204T2 HUE15838150A HUE15838150A HUE054204T2 HU E054204 T2 HUE054204 T2 HU E054204T2 HU E15838150 A HUE15838150 A HU E15838150A HU E15838150 A HUE15838150 A HU E15838150A HU E054204 T2 HUE054204 T2 HU E054204T2
Authority
HU
Hungary
Prior art keywords
compositions
treating
methods
preventing inflammation
inflammation
Prior art date
Application number
HUE15838150A
Other languages
English (en)
Inventor
Przemyslaw Sapieha
Normand Beaulieu
Original Assignee
Rsem Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rsem Lp filed Critical Rsem Lp
Publication of HUE054204T2 publication Critical patent/HUE054204T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
HUE15838150A 2014-09-05 2015-09-08 Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez HUE054204T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462046459P 2014-09-05 2014-09-05

Publications (1)

Publication Number Publication Date
HUE054204T2 true HUE054204T2 (hu) 2021-08-30

Family

ID=55438956

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15838150A HUE054204T2 (hu) 2014-09-05 2015-09-08 Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez

Country Status (17)

Country Link
US (4) US10738122B2 (hu)
EP (1) EP3189074B1 (hu)
JP (3) JP6692816B2 (hu)
KR (2) KR102696275B1 (hu)
CN (2) CN107207577B (hu)
AU (1) AU2015311563B2 (hu)
CA (1) CA2960054C (hu)
DK (1) DK3189074T3 (hu)
ES (1) ES2865488T3 (hu)
HR (1) HRP20210577T1 (hu)
HU (1) HUE054204T2 (hu)
LT (1) LT3189074T (hu)
PL (1) PL3189074T3 (hu)
PT (1) PT3189074T (hu)
RS (1) RS61703B1 (hu)
SI (1) SI3189074T1 (hu)
WO (1) WO2016033699A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2958580A4 (en) 2013-02-21 2016-09-21 Rsem Ltd Partnership INHIBITION OF SEMA3A IN THE PREVENTION AND TREATMENT OF OCULAR HYPERPERMEABILITY
JP6692816B2 (ja) 2014-09-05 2020-05-13 アールエスイーエム，リミティド パートナーシップ 炎症を処置および予防するための組成物および方法
EP3353196B1 (en) * 2015-09-22 2022-12-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides capable of inhibiting the binding between leptin and neuropilin-1
US20200056186A1 (en) 2016-09-22 2020-02-20 Rsem, Limited Partnership Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
EP3565896A1 (en) * 2017-01-09 2019-11-13 Secarna Pharmaceuticals GmbH & Co. KG Oligonucleotides inhibiting the expression of nrp1
JP6470879B1 (ja) * 2017-03-08 2019-02-13 日清オイリオグループ株式会社 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物
KR20220007128A (ko) * 2019-05-09 2022-01-18 베링거 인겔하임 인터내셔날 게엠베하 항-ｓｅｍａ３ａ 항체 및 눈 또는 안구 질환 치료를 위한 이의 용도
EP3983437A1 (en) 2019-06-12 2022-04-20 Novartis AG Natriuretic peptide receptor 1 antibodies and methods of use
TWI859339B (zh) * 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
CN112641928A (zh) * 2019-10-11 2021-04-13 田中纯美 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途
WO2021258218A1 (en) * 2020-06-26 2021-12-30 Semathera Inc. Use of soluble nrp1 polypeptides for the treatment of coronavirus infections
KR20230060504A (ko) * 2020-07-31 2023-05-04 파인트리 테라퓨틱스 인코포레이티드 바이러스 감염 치료를 위한 뉴로필린 및 안지오텐신 전환 효소 2 융합 펩티드
JP2024533320A (ja) 2021-09-08 2024-09-12 ユニベルシテ ドゥ ストラスブール プレキシン－ａ１の膜貫通ペプチド拮抗剤及びそれらの治療用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4806463A (en) 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
AUPM516994A0 (en) 1994-04-20 1994-05-12 Gene Shears Pty. Limited An in vivo gene expression system
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US20030032070A1 (en) 2001-07-20 2003-02-13 Mt. Sinai School Of Medicine Methods for diagnosing and treating alzheimer's disease and parkinson's disease
EP1429801A1 (en) 2001-09-26 2004-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neuropilin as a novel therapeutic target for modulation of immune reponses
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
CN101578376A (zh) * 2005-07-13 2009-11-11 貝丝以色列女执事医疗中心 诊断和治疗炎性应答的方法
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2008143666A2 (en) * 2007-05-17 2008-11-27 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
CN103193888B (zh) * 2007-05-17 2015-09-09 健泰科生物技术公司 神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构
WO2009060159A1 (en) 2007-11-08 2009-05-14 Medigene Limited Mutated ilt molecules
US20120322085A1 (en) * 2009-11-05 2012-12-20 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
WO2012031603A2 (en) * 2010-09-09 2012-03-15 Danish Medical Consults Aps Airway administration of angiogenesis inhibitors
WO2014123186A1 (ja) 2013-02-06 2014-08-14 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
EP2958580A4 (en) 2013-02-21 2016-09-21 Rsem Ltd Partnership INHIBITION OF SEMA3A IN THE PREVENTION AND TREATMENT OF OCULAR HYPERPERMEABILITY
JP6692816B2 (ja) 2014-09-05 2020-05-13 アールエスイーエム，リミティド パートナーシップ 炎症を処置および予防するための組成物および方法

Also Published As

Publication number Publication date
JP2017527616A (ja) 2017-09-21
AU2015311563B2 (en) 2019-11-28
WO2016033699A1 (en) 2016-03-10
CN113980116A (zh) 2022-01-28
LT3189074T (lt) 2021-06-10
JP7194146B2 (ja) 2022-12-21
RS61703B1 (sr) 2021-05-31
CN107207577A (zh) 2017-09-26
CA2960054C (en) 2023-11-14
PT3189074T (pt) 2021-04-19
CN107207577B (zh) 2021-11-09
AU2015311563A1 (en) 2017-03-16
PL3189074T3 (pl) 2021-08-02
US20210061915A1 (en) 2021-03-04
US20230265199A1 (en) 2023-08-24
US10766964B2 (en) 2020-09-08
US20170283502A1 (en) 2017-10-05
US20190359718A1 (en) 2019-11-28
CA2960054A1 (en) 2016-03-10
EP3189074B1 (en) 2021-01-13
EP3189074A1 (en) 2017-07-12
US10738122B2 (en) 2020-08-11
ES2865488T3 (es) 2021-10-15
KR102696275B1 (ko) 2024-08-21
SI3189074T1 (sl) 2021-08-31
JP2020147568A (ja) 2020-09-17
DK3189074T3 (da) 2021-04-19
EP3189074A4 (en) 2018-06-20
KR20170044691A (ko) 2017-04-25
KR20240125991A (ko) 2024-08-20
US11649292B2 (en) 2023-05-16
HRP20210577T1 (hr) 2021-05-28
JP6692816B2 (ja) 2020-05-13
JP2023022308A (ja) 2023-02-14

Similar Documents

Publication Publication Date Title
HK1243640A1 (zh) 用於治療潰瘍的方法和組合物
IL259576A (en) Preparations and methods for immuno-oncology
HK1248602A1 (zh) 治療癌症的組合物及方法
RS61703B1 (sr) Kompozicije i postupci za lečenje i prevenciju zapaljenja
IL250715A0 (en) Preparations and methods for the treatment of cultural disorders
IL251759A0 (en) Preparations and methods for treating insomnia
SMT202100273T1 (it) Metodi e composizioni per il trattamento del cancro
IL251108A0 (en) Preparations and methods for the treatment of acute radiation syndrome
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
IL255638A (en) Compositions and methods for treating cancer
IL250114B (en) Methods and compositions for the treatment of HIV-related diseases
ZA201605109B (en) Compositions and methods for treating neutropenia
EP3262065C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES
HK1246206A1 (zh) 用於治療青光眼的組合物和方法
PT3220908T (pt) Composições e métodos para o tratamento da endometriose
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
IL257407A (en) Compositions and methods for treating wounds
IL252707B (en) Compositions and methods for treating diseases
HK1250958A1 (zh) 用於治療癌症的組合物和方法
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201407949D0 (en) Compositions and methods for treating biofilms
GB201511447D0 (en) Compositions and methods for treating biofilms
GB201511051D0 (en) Compositions and methods for treating biofilms